Preclinical efficiency testing in a rat model of doxorubicin-induced cardiotoxicity reduction has demonstrated statistically significant protection.
February 5, 2018
Tosk has been awarded a $2 million grant from National Cancer Institute to continue the company’s TK-kRAS research program.
February 5, 2018

Tosk has had excellent though preliminary results of its recently inaugurated human trials for its TK-90 drug, which protects again mucositis.

Tosk has initiated human trials for its TK-90 drug, and preliminary results are encouraging. The drug is intended to reduce or eliminate the side effects of commonly administered drugs, which include the painful inflammation and ulceration of the mucous membranes lining the digestive tract.

The physicians involved with the dosing of the first three patients with head and neck cancer has provided positive feedback on the results. The next step in the clinical trail is to increase the dose of TK-90 on a new group of patients to determine if the protective effect against mucositis is improved while safety if maintained. The purpose of this process of dose escalation, a standard feature of clinical studies, is to establish the optimal dose of TK-90.